Key takeaways
Humira (adalimumab) and Simponi (golimumab) are both injectable medications used to treat autoimmune conditions, but they have some key differences. Humira is available in both brand and biosimilar forms, while Simponi is only available as a brand medication, which can make it more expensive. Humira is typically injected every other week, whereas Simponi is injected once a month, making Simponi more convenient for some people. Humira can be used for a wider range of conditions, including Crohn's disease and hidradenitis suppurativa, while Simponi is not approved for these conditions. Both medications block tumor necrosis factor (TNF) to reduce inflammation, but Simponi is also available as an intravenous infusion (Simponi Aria), which is administered by a healthcare provider. Additionally, Humira can be used in young children for certain conditions, whereas Simponi's prefilled syringe and autoinjector are only for adults, with children needing the IV infusion. Both medications raise the risk of serious infections and certain cancers, and neither should be used with live vaccines.
